Clinical Trial Update: A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ABT-751 in combination with Alimta for advanced non-small cell lung cancer has completed the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABT-751 (ABT-751)
• Alimta (pemetrexed)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Lung Cancer, NSCLC | Phase 1, Phase 2 | Status: COMPLETED